OxyContin maker Purdue Pharma has reached a tentative settlement with a coalition of states and local governments that sued the company over its role in America’s ongoing opioid crisis.
OxyContin maker Purdue Pharma has filed for Chapter 11 bankruptcy, touching off what could be a fierce battle by dozens of states hoping to recoup billions spent fighting the opioid crisis.
The Drug Enforcement Administration (DEA) is proposing a reduction in the amount of Schedule II controlled substances that can be manufactured in the US next year.
Settlement talks with OxyContin maker Purdue Pharma over its role in the U.S. opioid crisis have reached a stalemate and the company is expected to file for bankruptcy.
Recognition of the wide phenotype spectrum in immune checkpoint inhibitor-related neuropathy and prompt management with corticosteroids may lead to favorable outcomes.
Migraine is a potential risk factor for the development of traumatic brain injury (TBI) and is associated with a 78% increased risk for TBI compared with individuals without migraine.
Computed tomography-guided pulsed radiofrequency therapy may offer pain relief, improve quality of life, and reduce medication use in patients with trigeminal postherpetic neuralgia.
The FDA has granted Fast Track designation for IDCT (DiscGenics, Inc.), an investigational cell therapy for the reduction in pain and disability associated with degenerative disc disease (DDD).
Women with frequent episodic tension-type headache may have widespread pressure pain hypersensitivity in musculoskeletal structures and over nerve trunks.
